Table 3 Prevalence and prognostic significance of MR imaging features at diagnosis, first post-RT assessment, best response, and first radiographic progression
Diagnosis (N = 25) | First post-RT assessment (N = 22) | Best response (N = 22) | First radiographic progression (N = 18) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
N (%) | Hazard ratio | p value | N (%) | Hazard ratio | p value | N (%) | Hazard ratio | p value | N (%) | Hazard ratio | p value | |
Necrosis | 17 (68%) | 3.1 | 0.029 | 16 (73%) | 6.3 | 0.0049 | 17 (77%) | 7.9 | 0.0076 | 12 (67%) | 5.6 | 0.0099 |
New | – | – | – | 8 (36%) | 3.3 | 0.025 | 5 (23%) | 2.4 | 0.12 | 7 (39%) | 3.2 | 0.03 |
Increasing | – | – | – | 12 (55%) | 3.6 | 0.01 | 6 (27%) | 3.1 | 0.033 | 8 (44%) | 25 | 0.003 |
New and/or increasing | – | – | – | 12 (55%) | 3.6 | 0.01 | 6 (27%) | 3.1 | 0.033 | 9 (50%) | 4.3 | 0.0078 |
Decreasing | – | – | – | 4 (18%) | 1.4 | 0.53 | 10 (45%) | 1.9 | 0.16 | 3 (17%) | 0.94 | 0.93 |
Enhancement | 21 (84%) | 1.9 | 0.27 | 17 (81%) | 3.5 | 0.05 | 18 (86%) | 4 | 0.071 | 14 (78%) | 3.2 | 0.072 |
New | – | – | – | 6 (29%) | 2.6 | 0.075 | 4 (19%) | 1.8 | 0.33 | 9 (50%) | 4.1 | 0.012 |
Increasing | – | – | – | 12 (57%) | 4.1 | 0.0066 | 6 (29%) | 1.6 | 0.33 | 9 (50%) | > > 1 | 1 |
New and/or increasing | – | – | – | 12 (57%) | 4.1 | 0.0066 | 6 (29%) | 1.6 | 0.33 | 10 (56%) | 5.4 | 0.0036 |
Decreasing | – | – | – | 6 (29%) | 0.64 | 0.37 | 11 (52%) | 1.3 | 0.51 | 6 (33%) | 0.49 | 0.18 |
Peripheral ring like | 16 (64%) | 4.2 | 0.0077 | 14 (67%) | 5.3 | 0.0045 | 13 (62%) | 4.5 | 0.0059 | 10 (56%) | 5.4 | 0.0036 |
Patchy ill defined | 14 (56%) | 0.96 | 0.93 | 11 (52%) | 1.6 | 0.32 | 14 (67%) | 1.3 | 0.57 | 12 (67%) | 2.6 | 0.084 |
Diffusion restriction | 15 (60%) | 0.53 | 0.15 | 11 (50%) | 3.1 | 0.028 | 11 (50%) | 3.1 | 0.028 | 10 (56%) | 1.3 | 0.59 |
New | – | – | – | 7 (32%) | 2.4 | 0.074 | 3 (14%) | 5.2 | 0.027 | 6 (33%) | 0.71 | 0.56 |
Increasing | – | – | – | 7 (32%) | 2.4 | 0.074 | 5 (23%) | 6.3 | 0.0054 | 6 (33%) | 0.71 | 0.56 |
New and/or increasing | – | – | – | 7 (32%) | 2.4 | 0.074 | 5 (23%) | 6.3 | 0.0054 | 6 (33%) | 0.71 | 0.56 |
Decreasing | – | – | – | 6 (27%) | 1.1 | 0.78 | 5 (23%) | 0.73 | 0.55 | 2 (11%) | 1.6 | 0.54 |
Metastatic disease | 1 (4%) | 5.5 | 0.13 | 2 (9%) | 11 | 0.017 | 3 (14%) | 1.2 | 0.75 | 4 (22%) | 2 | 0.24 |
Hemorrhage | 11 (44%) | 1.3 | 0.56 | 16 (73%) | 2.2 | 0.14 | 16 (73%) | 2.2 | 0.14 | 13 (72%) | 0.96 | 0.94 |
New | – | – | – | 10 (45%) | 1.9 | 0.14 | 9 (41%) | 1.5 | 0.4 | 5 (28%) | 0.69 | 0.52 |
Increasing | – | – | – | 9 (41%) | 1.9 | 0.14 | 8 (36%) | 1.5 | 0.42 | 4 (22%) | 0.8 | 0.74 |
New and/or increasing | – | – | – | 10 (45%) | 1.9 | 0.14 | 9 (41%) | 1.5 | 0.4 | 5 (28%) | 0.69 | 0.52 |
Decreasing | – | – | – | 4 (18%) | 0.99 | 0.99 | 3 (14%) | 1.8 | 0.38 | 1 (6%) | 0.81 | 0.84 |